Voxelotor
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Anemia in Children
Conditions
Sickle Cell Anemia in Children
Trial Timeline
Mar 28, 2022 → Oct 22, 2024
NCT ID
NCT05018728About Voxelotor
Voxelotor is a phase 2 stage product being developed by Pfizer for Sickle Cell Anemia in Children. The current trial status is terminated. This product is registered under clinical trial identifier NCT05018728. Target conditions include Sickle Cell Anemia in Children.
What happened to similar drugs?
4 of 20 similar drugs in Sickle Cell Anemia in Children were approved
Approved (4) Terminated (9) Active (8)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03943615 | Pre-clinical | Completed |
| NCT04724421 | Pre-clinical | Completed |
| NCT06023199 | Phase 2 | Active |
| NCT05018728 | Phase 2 | Terminated |
| NCT04400487 | Approved | Completed |
| NCT04247594 | Phase 2 | Terminated |
| NCT04188509 | Phase 3 | Terminated |
| NCT03573882 | Phase 3 | Terminated |
| NCT03036813 | Phase 3 | Completed |
| NCT02850406 | Phase 2 | Terminated |
Competing Products
20 competing products in Sickle Cell Anemia in Children